{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:37:59Z","timestamp":1790811479356,"version":"4.1.0"},"reference-count":84,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The drugs used for cancer treatment have many drawbacks, as they damage both tumor and healthy cells and, in addition, they tend to be poorly soluble drugs. Their transport in nanoparticles can solve these problems as these can release the drug into tumor tissues, as well as improve their solubility, bioavailability, and efficacy, reducing their adverse effects. This article focuses on the advantages that nanotechnology can bring to medicine, with special emphasis on nanoliposomes. For this, a review has been made of the nanoliposomal systems marketed for the treatment of cancer, as well as those that are in the research phase, highlighting the clinical trials being carried out. All marketed liposomes studied are intravenously administered, showing a reduced intensity of side-effects compared with the nonliposomal form. Doxorubicin is the active ingredient most frequently employed. Ongoing clinical trials expand the availability of liposomal medicines with new clinical indications. In conclusion, the introduction of drugs in nanoliposomes means an improvement in their efficacy and the quality of life of patients. The future focus of research could be directed to develop multifunctional targeted nanoliposomes using new anticancer drugs, different types of existing drugs, or new standardized methodologies easily translated into industrial scale.<\/jats:p>","DOI":"10.3390\/ijms23084249","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T21:15:35Z","timestamp":1649798135000},"page":"4249","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials"],"prefix":"10.3390","volume":"23","author":[{"given":"Raquel","family":"Tal\u00e9ns-Visconti","sequence":"first","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, Pharmacy Faculty, University of Valencia, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"D\u00edez-Sales","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, Pharmacy Faculty, University of Valencia, 46100 Valencia, Spain"},{"name":"Instituto Interuniversitario de Investigaci\u00f3n de Reconocimiento Molecular y Desarrollo Tecnol\u00f3gico (IDM), Universitat Polit\u00e8cnica de Val\u00e8ncia, Av. Vicent Andr\u00e9s Estell\u00e9s s\/n, Burjassot, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-8744","authenticated-orcid":false,"given":"Jesus Vicente","family":"de Juli\u00e1n-Ortiz","sequence":"additional","affiliation":[{"name":"Molecular Topology and Drug Design Research Unit, Department of Physical Chemistry, Pharmacy Faculty, University of Valencia, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1707-7966","authenticated-orcid":false,"given":"Amparo","family":"N\u00e1cher","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, Pharmacy Faculty, University of Valencia, 46100 Valencia, Spain"},{"name":"Instituto Interuniversitario de Investigaci\u00f3n de Reconocimiento Molecular y Desarrollo Tecnol\u00f3gico (IDM), Universitat Polit\u00e8cnica de Val\u00e8ncia, Av. Vicent Andr\u00e9s Estell\u00e9s s\/n, Burjassot, 46100 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"ref_1","unstructured":"International Agency for Research on Cancer (2022, February 17). Elaborated Online on the Website Global Cancer Observatory. Available online: https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/bars?types=0&sexes=0&mode=cancer&group_populations=0&multiple_populations=0&multiple_cancers=1&cancers=10_9_1_3_5_7_12_16_36_2_4_6_8_13_11_14_15_17_18_19_20_21_23_22_24_25_26_27_28_29_30_31_32_33_34&populations=900&bar_mode=stacked&group_cancers=0&key=total&show_bar_mode_prop=1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.colsurfb.2019.05.008","article-title":"Therapeutic and diagnostic potential of nanomaterials for enhanced biomedical applications","volume":"180","author":"Abdelrahman","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1900426","DOI":"10.1002\/marc.201900426","article-title":"Recombinant Spider Silk\u2013Silica Hybrid Scaffolds with Drug-Releasing Properties for Tissue Engineering Applications","volume":"41","author":"Kumari","year":"2019","journal-title":"Macromol. Rapid Commun."},{"key":"ref_4","unstructured":"EMA (2022, February 20). Nanotechnology, Available online: https:\/\/www.ema.europa.eu\/en\/glossary\/nanotechnology."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2000153","DOI":"10.1002\/smll.202000153","article-title":"All Roads Lead to the Liver: Metal Nanoparticles and Their Implications for Liver Health","volume":"16","author":"Boey","year":"2020","journal-title":"Small"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jconrel.2015.10.049","article-title":"Nanoparticles and Nanofibers for Topical Drug Delivery","volume":"240","author":"Goyal","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yoo, J., Park, C., Yi, G., Lee, D., and Koo, H. (2019). Active Targeting Strategies Using Biological Ligands for Nanoparticle Drug Delivery Systems. Cancers, 11.","DOI":"10.3390\/cancers11050640"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1021\/mp800051m","article-title":"Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles","volume":"5","author":"Alexis","year":"2008","journal-title":"Mol. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jpba.2015.11.027","article-title":"Pre-Clinical Investigation of the Modulation of Quetiapine Plasma Pharmacokinetics and Tissues Biodistribution by Lipid-Core Nanocapsules","volume":"119","author":"Paese","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1600279","DOI":"10.1002\/advs.201600279","article-title":"Nanoparticle Functionalization and Its Potentials for Molecular Imaging","volume":"4","author":"Thiruppathi","year":"2016","journal-title":"Adv. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"119429","DOI":"10.1016\/j.ijpharm.2020.119429","article-title":"Spray-Dried Raloxifene Submicron Particles for Pulmonary Delivery: Development and in Vivo Pharmacokinetic Evaluation in Rats","volume":"585","author":"Fontana","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Teleanu, D., Chircov, C., Grumezescu, A., and Teleanu, R. (2019). Neurotoxicity of Nanomaterials: An up-to-Date Overview. Nanomaterials, 9.","DOI":"10.3390\/nano9010096"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425247.2013.769956","article-title":"Poly(\u03f5-Caprolactone) Microcapsules and Nanocapsules in Drug Delivery","volume":"10","author":"Pohlmann","year":"2013","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: An Update on Anticancer Molecular Action, Toxicity and Novel Drug Delivery Systems","volume":"65","author":"Tacar","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_15","unstructured":"Mohapatra, S.S., Ranjan, S., Dasgupta, N., Mishra, R.K., and Thomas, S. (2019). Administration Routes for Nano Drugs and Characterization of Nano Drug Loading. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery, Elsevier."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-018-1284-9","article-title":"Insights on Oral Drug Delivery of Lipid Nanocarriers: A Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs","volume":"20","author":"Nabi","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2217\/nnm-2020-0116","article-title":"Innovative Strategies to Treat Skin Wounds with Mangiferin: Fabrication of Transfersomes Modified with Glycols and Mucin","volume":"15","author":"Allaw","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.2147\/IJN.S302161","article-title":"Development and Evaluation of Curcumin Encapsulated Self-Assembled Nanoparticles as Potential Remedial Treatment for PCOS in a Female Rat Model","volume":"16","author":"Raja","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1002\/fsn3.2562","article-title":"Development of Curcumin-Loaded Prunus Armeniaca Gum Nanoparticles: Synthesis, Characterization, Control Release Behavior, and Evaluation of Anticancer and Antimicrobial Properties","volume":"9","author":"Salarbashi","year":"2021","journal-title":"Food Sci. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1872210515666210428135343","article-title":"Nanotechnology Based Herbal Formulations: A Survey of Recent Patents, Advancements and Transformative Headways","volume":"16","author":"Kaur","year":"2022","journal-title":"Recent Pat. Nanotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrd4333","article-title":"Multifunctional, Stimuli-Sensitive Nanoparticulate Systems for Drug Delivery","volume":"13","author":"Torchilin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Xia, W., Tao, Z., Zhu, B., Zhang, W., Liu, C., Chen, S., and Song, M. (2021). Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179118"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-2836(65)80093-6","article-title":"Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids","volume":"13","author":"Bangham","year":"1965","journal-title":"J. Mol. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.bi.41.070172.003541","article-title":"Lipid bilayers and biomembranes","volume":"41","author":"Bangham","year":"1972","journal-title":"Annu. Rev. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/10942910701648115","article-title":"Encapsulation of Food Ingredients Using Nanoliposome Technology","volume":"11","author":"Mozafari","year":"2008","journal-title":"Int. J. Food Prop."},{"key":"ref_26","first-page":"1","article-title":"Liposomes as Potential Drug Carrier Systems for Drug Delivery","volume":"1","author":"Sezer","year":"2014","journal-title":"Appl. Nanotechnol. Drug Deliv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/08982100802310261","article-title":"Differential Scanning Calorimetry (DSC): A tool to study the thermal behavior of lipid bilayers and liposomal stability","volume":"18","author":"Demetzos","year":"2008","journal-title":"J. Liposome Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3109\/10717544.2015.1074765","article-title":"Advances in Nanotechnology-Based Carrier Systems for Targeted Delivery of Bioactive Drug Molecules with Special Emphasis on Immunotherapy in Drug Resistant Tuberculosis\u2014A Critical Review","volume":"23","author":"Singh","year":"2015","journal-title":"Drug Deliv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0009-3084(93)90071-A","article-title":"Liposomes: The babraham connection","volume":"64","author":"Bangham","year":"1993","journal-title":"Chem. Phys. Lipids"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1038\/srep05005","article-title":"Cholesterol level affects surface charge of lipid membranes in saline solution","volume":"4","author":"Magarkar","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.eq.2016.07.002","article-title":"La Nanomedicina y Los Sistemas De Liberaci\u00f3n De F\u00e1rmacos: \u00bfLa (R)Evoluci\u00f3n De La Terapia Contra El C\u00e1ncer?","volume":"27","year":"2016","journal-title":"Educ. Qu\u00edmica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: Classification, Preparation, and Applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/03639045.2017.1301948","article-title":"Effects of Surface Charge of Low Molecular Weight Heparin-Modified Cationic Liposomes on Drug Efficacy and Toxicity","volume":"43","author":"Li","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/1061186X.2021.1992630","article-title":"Nanoliposomes as Drug Delivery Systems: Safety Concerns","volume":"30","author":"Tereshkina","year":"2021","journal-title":"J. Drug Target."},{"key":"ref_35","first-page":"133","article-title":"Drug Delivery and Nanoparticles: Applications and Hazards","volume":"3","author":"Borm","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejpb.2022.01.009","article-title":"Elucidating Inhaled Liposome Surface Charge on Its Interaction with Biological Barriers in the Lung","volume":"172","author":"Zhao","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1248\/cpb.43.1005","article-title":"Physical-Chemistry Characteristics and Biodistribution of Poly(ethylene glycol)-Coated Liposomes Using Poly(oxyethylene) Cholesteryl Ether","volume":"43","author":"Ishiwata","year":"1995","journal-title":"Chem. Pharm. Bull."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1021\/bm200658b","article-title":"Sonoproduction of Liposomes and Protein Particles as Templates for Delivery Purposes","volume":"12","author":"Silva","year":"2011","journal-title":"Biomacromolecules"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1016\/j.biomaterials.2012.03.084","article-title":"Gadolinium Loaded Nanoparticles in Theranostic Magnetic Resonance Imaging","volume":"33","author":"Liu","year":"2012","journal-title":"Biomaterials"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e2100639","DOI":"10.1002\/adhm.202100639","article-title":"Liposomes and Extracellular Vesicles as Drug Delivery Systems: A Comparison of Composition, Pharmacokinetics, and Functionalization","volume":"11","author":"Koog","year":"2021","journal-title":"Adv. Healthc. Mater."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1166\/jcsb.2012.1020","article-title":"Preparation, Characterization and Applications of Liposomes: State of the Art","volume":"1","author":"Laouini","year":"2012","journal-title":"J. Colloid Sci. Biotechnol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/0008-5472.CAN-12-4561","article-title":"Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology","volume":"73","author":"Prabhakar","year":"2013","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"149","DOI":"10.22270\/jddt.v11i5-S.5063","article-title":"Liposomes as Drug Delivery System: An Updated Review","volume":"11","author":"Farooque","year":"2021","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and Challenges of Liposome Assisted Drug Delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1080\/17425247.2020.1772749","article-title":"Harnessing CD47 Mimicry to Inhibit Phagocytic Clearance and Enhance Anti-Tumor Efficacy of Nanoliposomal Doxorubicin","volume":"17","author":"Jaafari","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2230-973X.108958","article-title":"Novel gene delivery systems","volume":"3","author":"Manjila","year":"2013","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1021\/acsnano.1c07687","article-title":"Opsonin-Deficient Nucleoproteic Corona Endows Unpegylated Liposomes with Stealth Properties in Vivo","volume":"16","author":"Giulimondi","year":"2022","journal-title":"ACS Nano"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.addr.2012.06.006","article-title":"Nanotheranostics for personalized medicine","volume":"64","author":"Mura","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2015.10.019","article-title":"\u201cCombo\u201d Nanomedicine: Co-Delivery of Multi-Modal Therapeutics for Efficient, Targeted, and Safe Cancer Therapy","volume":"98","author":"Kemp","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100024","DOI":"10.1016\/j.medidd.2020.100024","article-title":"Combination Therapy Based on Nano Codelivery for Overcoming Cancer Drug Resistance","volume":"6","author":"Wang","year":"2020","journal-title":"Med. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled Drug Delivery Vehicles for Cancer Treatment and Their Performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.drudis.2010.08.006","article-title":"Cancer Nanotechnology: Application of Nanotechnology in Cancer Therapy","volume":"15","author":"Misra","year":"2010","journal-title":"Drug Discov. Today"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in Cancer Therapy: Challenges, Opportunities, and Clinical Applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jconrel.2015.08.041","article-title":"Cancer Targeted Therapeutics: From Molecules to Drug Delivery Vehicles","volume":"219","author":"Liu","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Gilabert-Oriol, R., Ryan, G., Leung, A., Firmino, N., Bennewith, K., and Bally, M. (2018). Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102922"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Barbato, L., Bocchetti, M., Di Biase, A., and Regad, T. (2019). Cancer stem cells and targeting strategies. Cells, 8.","DOI":"10.3390\/cells8080926"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2017.00001","article-title":"Nanomaterials in targeting cancer stem cells for cancer therapy","volume":"8","author":"Qin","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1021\/acsbiomaterials.1c00110","article-title":"Cancer stem cell-targeted gene delivery mediated by aptamer-decorated ph-sensitive Nanoliposomes","volume":"7","author":"Moitra","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.msec.2014.04.049","article-title":"Drug Delivery Vehicles on a Nano-Engineering Perspective","volume":"41","author":"Felice","year":"2014","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (Vincristine Sulfate Liposome Injection) Improves the Pharmacokinetics and Pharmacodynamics of Vincristine","volume":"71","author":"Silverman","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014the First FDA-Approved Nano-Drug: Lessons Learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_63","unstructured":"(2022, February 28). Current Nanotechnology Treatments, Available online: https:\/\/www.cancer.gov\/nano\/cancer-nanotechnology\/current-treatments."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.farma.2011.05.006","article-title":"Farmacocin\u00e9tica Poblacional De Doxorubicina Aplicada a La Personalizaci\u00f3n De Su Dosificaci\u00f3n En Pacientes Oncol\u00f3gicos","volume":"36","author":"Duart","year":"2012","journal-title":"Farm. Hosp."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New Insights and Evolving Role of Pegylated Liposomal Doxorubicin in Cancer Therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4103\/0973-1482.139267","article-title":"An Overview of Doxorubicin Formulations in Cancer Therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J. Cancer Res. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","article-title":"Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_68","unstructured":"The European Medicines Agency\u2014Caelyx (2022, April 06). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/caelyx-epar-product-information_es.pdf."},{"key":"ref_69","unstructured":"(2022, April 06). Ministerio de Sanidad Informe de Posicionamiento Terap\u00e9utico de Irinotecan Liposomal P\u00e1ncreas Metast\u00e1sico. Available online: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-irinotecan-liposomal-pegilado-Onivyde-cancer-pancreas.pdf?x17133."},{"key":"ref_70","first-page":"277","article-title":"Liposomal daunorubicin as treatment for Kaposi\u2019s sarcoma","volume":"2","author":"Petre","year":"2007","journal-title":"Int. J. Nanomed."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/10428190500052438","article-title":"The Use of Liposomal Daunorubicin (DaunoXome) in Acute Myeloid Leukemia","volume":"46","author":"Fassas","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_72","unstructured":"(2022, February 28). Kaposi Sarcoma Treatment (PDQ\u00ae)\u2013Health Professional Version, Available online: https:\/\/www.cancer.gov\/types\/soft-tissue-sarcoma\/hp\/kaposi-treatment-pdq."},{"key":"ref_73","unstructured":"(2022, March 05). Vyxeos liposomal1 (daunorubicin \/ cytarabine). An Overview of Vyxeos Liposomal and Why It Is Authorised in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vyxeos-liposomal-epar-medicine-overview_en.pdf."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2008.06.028","article-title":"In Vivo Maintenance of Synergistic Cytarabine: Daunorubicin Ratios Greatly Enhances Therapeutic Efficacy","volume":"33","author":"Tardi","year":"2009","journal-title":"Leuk. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 Trial of CPX-351, a Fixed 5:1 Molar Ratio of Cytarabine\/Daunorubicin, vs Cytarabine\/Daunorubicin in Older Adults with Untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (Cytarabine and Daunorubicin) Liposome for Injection versus Conventional Cytarabine plus Daunorubicin in Older Patients with Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_77","unstructured":"(2022, April 06). Zolsketil Pegylated Liposomal-Ema.Europa.Eu. (n.d.) Retrieved 7 April 2022. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/smop-initial\/chmp-summary-opinion-zolsketil-pegylated-liposomal_en.pdf."},{"key":"ref_78","unstructured":"(2022, February 28). Efficacy and Safety of Paclitaxel Liposome and S-1 as First-Line Therapy in Advanced Pancreatic Cancer Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04217096."},{"key":"ref_79","unstructured":"(2022, February 28). Evaluation of PLD Combined with Carboplatin Versus Paclitaxel Plus Carboplatin in the First-Line Treatment of Epithelial Ovarian Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03794778."},{"key":"ref_80","unstructured":"(2022, February 28). Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01906385."},{"key":"ref_81","unstructured":"(2022, February 28). Study of C6 Ceramide NanoLiposome (CNL) in Patients with Relapsed\/Refractory Acute Myeloid Leukemia, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04716452."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1515\/hsz-2015-0129","article-title":"Preclinical Development of a C6-Ceramide Nanoliposome, a Novel Sphingolipid Therapeutic","volume":"396","author":"Kester","year":"2015","journal-title":"Biol. Chem."},{"key":"ref_83","unstructured":"(2022, February 28). Liposomal SN-38 in Treating Patients with Metastatic Colorectal Cancer, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00311610."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1200\/jco.2008.26.15_suppl.4109","article-title":"Le-sn38 for Metastatic Colorectal Cancer after Progression on Oxaliplatin: Results of CALGB 80402","volume":"26","author":"Ocean","year":"2008","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4249\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:52:12Z","timestamp":1760136732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":84,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23084249"],"URL":"https:\/\/doi.org\/10.3390\/ijms23084249","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]}}}